M
Mark Mirochnick
Researcher at Boston University
Publications - 153
Citations - 8619
Mark Mirochnick is an academic researcher from Boston University. The author has contributed to research in topics: Pregnancy & Population. The author has an hindex of 45, co-authored 142 publications receiving 8036 citations. Previous affiliations of Mark Mirochnick include Johns Hopkins University & University of Massachusetts Amherst.
Papers
More filters
Journal ArticleDOI
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
Laura Guay,Philippa Musoke,Thomas Fleming,Danstan Bagenda,Melissa Allen,Clemensia Nakabiito,Joseph Sherman,Paul M Bakaki,Constance Ducar,Martina Deseyve,Lynda Emel,Mark Mirochnick,Mary Glenn Fowler,Lynne M. Mofenson,Paolo G. Miotti,Kevin Dransfield,Dorothy Bray,Francis Mmiro,J. Brooks Jackson +18 more
TL;DR: Nevirapine lowered the risk of HIV-1 transmission during the first 14-16 weeks of life by nearly 50% in a breastfeeding population, suggesting this simple and inexpensive regimen could decrease mother-to-child HIV- 1 transmission in less-developed countries.
Journal ArticleDOI
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
J. Brooks Jackson,Philippa Musoke,Thomas Fleming,Thomas Fleming,Laura Guay,Danstan Bagenda,Melissa Allen,Clemensia Nakabiito,Joseph Sherman,Paul M Bakaki,Maxensia Owor,Constance Ducar,Martina Deseyve,Anthony Mwatha,Lynda Emel,Corey Duefield,Mark Mirochnick,Mary Glenn Fowler,Lynne M. Mofenson,Paolo G. Miotti,Maria Gigliotti,Dorothy Bray,Francis Mmiro +22 more
TL;DR: Intrapartum/ne ononatal nevirapine significantly lowered HIV-1 transmission risk in a breastfeeding population in Uganda compared with a short intrapartu/neonatal zidovudine regimen.
Journal ArticleDOI
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Susan H. Eshleman,Martin Mracna,Laura Guay,Martina Deseyve,Shawn Cunningham,Mark Mirochnick,Philippa Musoke,Thomas Fleming,Mary Glenn Fowler,Lynne M. Mofenson,Francis Mmiro,J. Brooks Jackson +11 more
TL;DR: NVPR was detected more frequently in infants than women following NVP prophylaxis, and different patterns of NVPR mutations were detected in women versus infants, and NVP-resistant HIV-1 faded from detection in women and infants over time.
Journal ArticleDOI
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
Alejandro Dorenbaum,Coleen K. Cunningham,Richard D. Gelber,Mary Culnane,Lynne M. Mofenson,Paula Britto,Claire Rekacewicz,Marie-Louise Newell,Jean François Delfraissy,Bethann Cunningham-Schrader,Mark Mirochnick,John L. Sullivan +11 more
TL;DR: A 2-dose intrapartum/newborn nevirapine regimen reduced perinatal human immunodeficiency virus (HIV) transmission in Ugandan women not receiving antenatalantiretroviral therapy (ART).
Journal ArticleDOI
A phase I / II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).
Philippa Musoke,Laura Guay,Danstan Bagenda,Mark Mirochnick,Clemensia Nakabiito,Thomas Fleming,Terry Elliott,Scott Horton,Kevin Dransfield,Joseph W. Pav,Amal Murarka,Melissa Allen,Mary Glenn Fowler,Lynne M. Mofenson,David L. Hom,Francis Mmiro,J. Brooks Jackson +16 more
TL;DR: The administration of a single dose of nevirapine to women during labor and to their newborns at 72 h was well tolerated and showed potent antiretroviral activity in the women at 1 week after dosing without rebound above baseline 6 weeks after a single doses.